[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:lymphoplasmacytic-lymphoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":107,"states":108},"Lymphoplasmacytic Lymphoma",16,[7,15,21,28,34,40,46,52,58,64,70,77,83,89,95,101],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07231952","A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)\u002FLymphoplasmacytic Lymphoma (LPL)",[11],"Phase 2","RECRUITING","2026-08-26T02:18:35.425468Z","2026-05-05T02:43:29.135309Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT04840602","Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia\u002FLymphoplasmacytic Lymphoma",[11],"2026-08-26T02:15:53.461103Z","2026-05-05T02:43:29.075935Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT04545762","Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma",[25],"Phase 1","2026-08-26T02:18:03.638950Z","2026-07-05T03:45:20.448716Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT06708897","A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas",[25],"2026-08-26T02:17:57.117858Z","2026-05-05T02:43:29.367440Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":38,"content_modified":39},"NCT05544019","Study of SGR-1505 in Mature B-Cell Neoplasms",[25],"2026-08-26T02:15:49.658025Z","2026-05-05T02:43:28.973931Z",{"nct_id":41,"title":42,"phases":43,"status":12,"updated_at":44,"content_modified":45},"NCT04883437","Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",[11],"2026-08-26T02:18:27.904411Z","2026-05-05T02:43:28.560079Z",{"nct_id":47,"title":48,"phases":49,"status":12,"updated_at":50,"content_modified":51},"NCT03314974","Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders",[11],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:28.206546Z",{"nct_id":53,"title":54,"phases":55,"status":12,"updated_at":56,"content_modified":57},"NCT05805605","Allo HSCT Using RIC and PTCy for Hematological Diseases",[11],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.075410Z",{"nct_id":59,"title":60,"phases":61,"status":12,"updated_at":62,"content_modified":63},"NCT06340737","AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w\u002FRecurrent\u002FRefractory B Cell Lymphomas",[25],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.925479Z",{"nct_id":65,"title":66,"phases":67,"status":12,"updated_at":68,"content_modified":69},"NCT04195633","Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies",[11],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:27.479357Z",{"nct_id":71,"title":72,"phases":73,"status":12,"updated_at":75,"content_modified":76},"NCT03537482","APG-2575 Study of Safety, Tolerability ,PK\u002FPD in Patients With Hematologic Malignancies",[74],"Early Phase 1","2026-08-26T02:16:45.157238Z","2026-05-05T02:43:27.097841Z",{"nct_id":78,"title":79,"phases":80,"status":12,"updated_at":81,"content_modified":82},"NCT05281809","Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",[11],"2026-08-26T02:19:03.581490Z","2026-04-29T02:57:57.140676Z",{"nct_id":84,"title":85,"phases":86,"status":12,"updated_at":87,"content_modified":88},"NCT06636175","64Cu-LLP2A for Imaging Hematologic Malignancies",[74],"2026-08-26T02:18:51.009190Z","2026-05-05T02:43:28.740573Z",{"nct_id":90,"title":91,"phases":92,"status":12,"updated_at":93,"content_modified":94},"NCT00923507","Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL), Lymphoplasmacytic Lymphoma (LPL)\u002FWaldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)",[],"2026-08-26T02:17:42.501124Z","2026-05-13T02:55:06.065687Z",{"nct_id":96,"title":97,"phases":98,"status":12,"updated_at":99,"content_modified":100},"NCT03557619","A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies",[25],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:28.854165Z",{"nct_id":102,"title":103,"phases":104,"status":12,"updated_at":105,"content_modified":106},"NCT06860880","Combating Cancer-Related Fatigue: A Personalized Supportive Care Program",[],"2026-08-26T02:16:57.705506Z","2026-05-05T02:43:28.349178Z",[],[109,113,117,121,124,127,130,133,136],{"state":110,"count":111,"slug":112},"North Carolina",5,"north-carolina",{"state":114,"count":115,"slug":116},"Ohio",4,"ohio",{"state":118,"count":119,"slug":120},"California",3,"california",{"state":122,"count":119,"slug":123},"Florida","florida",{"state":125,"count":119,"slug":126},"Minnesota","minnesota",{"state":128,"count":119,"slug":129},"New Jersey","new-jersey",{"state":131,"count":119,"slug":132},"New York","new-york",{"state":134,"count":119,"slug":135},"Texas","texas",{"state":137,"count":119,"slug":138},"Washington","washington"]